Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study

DL Forrest, K Thompson, VG Dorcas… - Bone marrow …, 2003 - nature.com
We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and
hematopoietic stem cell transplantation (HSCT)(allogeneic (22), autologous (18)) to …
被引用次数：88 相关文章

Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study

DL Forrest, K Thompson, VG Dorcas… - Bone marrow …, 2003 - pubmed.ncbi.nlm.nih.gov
We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and
hematopoietic stem cell transplantation (HSCT)(allogeneic (22), autologous (18)) to …

[引用][C] Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II …

DL Forrest, K Thompson, VG Dorcas… - Bone Marrow …, 2003 - cir.nii.ac.jp
Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after
hematopoietic stem cell transplantation: a prospective phase II study | CiNii Research CiNii 国立 …
[PDF] academia.edu

[PDF][PDF] Post-transplant complications Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell …

DL Forrest, K Thompson, VG Dorcas… - Bone Marrow …, 2003 - academia.edu
We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and
hematopoietic stem cell transplantation (HSCT)(allogeneic (22), autologous (18)) to …
[HTML] nih.gov

[HTML][HTML] Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II …

DL Forrest, K Thompson, VG Dorcas… - Bone Marrow …, 2003 - ncbi.nlm.nih.gov
We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and
hematopoietic stem cell transplantation (HSCT)(allogeneic (22), autologous (18)) to …

Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study.

DL Forrest, K Thompson, VG Dorcas… - Bone Marrow …, 2003 - search.ebscohost.com
We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and
hematopoietic stem cell transplantation (HSCT)(allogeneic (22), autologous (18)) to …

Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study.

DL Forrest, K Thompson, VG Dorcas… - Bone Marrow …, 2003 - europepmc.org
We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and
hematopoietic stem cell transplantation (HSCT)(allogeneic (22), autologous (18)) to …
[PDF] researchgate.net

[PDF][PDF] Post-transplant complications Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell …

DL Forrest, K Thompson, VG Dorcas… - Bone Marrow …, 2003 - researchgate.net
We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and
hematopoietic stem cell transplantation (HSCT)(allogeneic (22), autologous (18)) to …

Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study

DL Forrest, K Thompson, VG Dorcas… - Bone Marrow …, 2003 - go.gale.com
We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and
hematopoietic stem cell transplantation (HSCT)(allogeneic (22), autologous (18)) to …

[引用][C] Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II …

DL FORREST, K THOMPSON… - Bone marrow …, 2003 - pascal-francis.inist.fr
Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD)
after hematopoietic stem cell transplantation: a prospective phase II study CNRS Inist Pascal-Francis …